MiR-92 suppresses proliferation and induces apoptosis by targeting EP4/Notch1 axis in gastric cancer

Oncotarget
Vivian Yvonne ShinKent-Man Chu

Abstract

MiR-92a has been shown to be dysregulated in various cancers and exhibited differential role in carcinogenesis. In this study, we sought to delineate the functional role of miR-92a and its regulatory pathway in gastric cancer. MiR-92a expression were underexpressed in tissues of gastric cancer patients with the area under curve (AUC) of 0.78. Low expression in plasma was due to the increased promoter DNA methylation of miR-92a. Overexpression of miR-92a inhibited cell proliferation and invasion, and induced apoptosis. Furthermore, miR-92a reduced tumor growth in xenograft model. EP4 and Notch 1 were identified to be negatively regulated by miR-92a, and involved in cell growth. Moreover, NF-κB expression was inversely correlated with miR-92a in gastric cancer tissues and suppressed the expression of miR-92. This study unravels the tumor suppressive role of miR-92a involving EP4/Notch 1 signaling regulated by NF-κB in gastric cancer. Further studies on miR-92a and EP4/Notch1 may provide a new treatment strategy for gastric cancer.

References

Feb 20, 2004·Proceedings of the National Academy of Sciences of the United States of America·George Adrian CalinCarlo M Croce
Jun 24, 2004·Nature Reviews. Genetics·Lin He, Gregory J Hannon
Jun 10, 2005·Nature·Lin HeScott M Hammond
Jun 10, 2005·Nature·Jun LuTodd R Golub
Feb 8, 2006·Proceedings of the National Academy of Sciences of the United States of America·Stefano VoliniaCarlo M Croce
May 18, 2007·Annual Review of Cell and Developmental Biology·Natascha Bushati, Stephen M Cohen
Mar 17, 2009·International Journal of Oncology·Kazuo MotoyamaMasaki Mori
Jun 4, 2010·Pathology International·Masatoshi ShigokaMasahiko Kuroda
Oct 16, 2010·PloS One·Ândrea Ribeiro-dos-SantosSylvain Darnet
Dec 15, 2010·The Journal of Biological Chemistry·Zhao-li ChenJie He
Apr 7, 2011·Archives of Pathology & Laboratory Medicine·Yuan SunHong Li
Oct 7, 2011·Molecular Carcinogenesis·Yun-Chien TsengTien-Shun Yeh
Dec 6, 2011·The Journal of Pharmacology and Experimental Therapeutics·Koichi IwanagaHiroshi Ozaki
Mar 29, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Naohiro NishidaMasaki Mori
May 30, 2012·Laboratory Investigation; a Journal of Technical Methods and Pathology·Xiping XinPeeyush K Lala
Apr 24, 2015·British Journal of Cancer·V Y ShinA Kwong
Nov 27, 2015·Molecular Cancer·Vivian Yvonne ShinKent-Man Chu

❮ Previous
Next ❯

Citations

Feb 29, 2020·International Journal of Molecular Sciences·Manuel Alvarez-RodriguezHeriberto Rodriguez-Martinez
Mar 11, 2020·International Journal of Molecular Sciences·Ana Carolina AnauateMarília Arruda Cardoso Smith
Jul 13, 2020·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·S FengW Zhu
Dec 10, 2020·Nature Reviews. Drug Discovery·Samarpan MajumderLucio Miele

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection
xenograft
flow cytometry
ELISA
PCR
surgical resection
X-ray

Software Mentioned

DP controller

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.